AxoSim, Inc.
AxoSim empowers advancements in human neuroscience and is mission-driven to advance 3-D organoid neurodiscovery models, also known as microphysiological systems, with the potential to jumpstart the discovery and development of breakthrough therapies. Partnering with biopharma companies, AxoSim facilitates therapeutic innovation by empowering drug developers to obtain relevant human data early in the R&D process, reducing the time and cost of drug discovery and increasing the probability of success. The company’s proprietary drug discovery platforms NerveSim®, BrainSim® and microBrain™ deliver clinically relevant functional data, enabling selection of better lead candidates with phenotypically accurate assays. AxoSim's platforms currently have applications in peripheral neuropathy and neuropathic pain, multiple sclerosis, seizure disorders, neurotoxicology, and other diseases. For more information, visit www.axosim.com.
- Industries
-
Biotechnology
- Office Locations
- New Orleans, Louisiana
- Contact Information
-
Gina Jackson
Director of Corporate Communications
[email protected]
Latest
Journalists and Bloggers
The news you need, when you need it.
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.
LEARN MORE